NEW YORK (GenomeWeb News) — Enzyme developer Dyadic International today said it has generated around $12.6 million in a private stock placement.
 
Dyadic said it will use roughly $12.3 million of the placement to expand its C1 Host Technology, which is used in the production of biomass production, and potentially in human antibody and therapeutic protein production.
 
The company also plans to use some funds to speed up the launch of new enzyme products, R&D and marketing.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.